CBLC137 clinical trials
Also written CBL0137.
How each study uses CBLC137 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the CBLC137 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
5 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2013 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2022 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 2 · Other 3
Incuron (2) · Children's Oncology Group (1) · Fox Chase Cancer Center (1) · Roswell Park Cancer Institute (1)
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2
Studies that test CBLC137.
- Dec 2026CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaPhase 1/2 · Children's Oncology Group
- Mar 2027Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaEarly Phase 1 · Fox Chase Cancer Center
Studies
Open first, then newest update. How each study uses CBLC137 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 5
- CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and LymphomaRecruitingPhase 1/2Children's Oncology GroupNCT04870944Written as FACT Complex-targeting Curaxin CBL0137
- Study of CBL0137 in Combination With Ipilimumab and Nivolumab Therapy in MelanomaRecruitingEarly Phase 1Fox Chase Cancer CenterNCT05498792Written as CBL0137
- CBL0137 in Treating Patients With Advanced Extremity Melanoma or SarcomaTerminatedPhase 1Roswell Park Cancer InstituteNCT03727789Written as FACT Complex-targeting Curaxin CBL0137
- A Phase 1 Trial of CBL0137 in Patients With Metastatic or Unresectable Advanced Solid NeoplasmCompletedPhase 1IncuronNCT01905228Written as CBL0137
- Study of IV CBL0137 in Previously Treated Hematological SubjectsTerminatedPhase 1IncuronNCT02931110Written as CBL0137
Codes
What other systems call CBLC137 · ClinicalTrials.gg INT000295
- MeSH (NLM) C000600493CBLC137One source ClinicalTrials.gov
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000600493 | CBLC137 | One source ClinicalTrials.gov |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.